A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment

Condition: Cancer of the Prostate


  • Radiation: Fluciclovine 18 F

Purpose: The main aim is to assess the impact of using fluciclovine (18F) (as a PET imaging radiotracer) on the clinical and treatment decision required for managing patients with biochemically recurrent prostate cancer (BCR) who are being considered for salvage treatment with the intention of providing disease cure. Also, this study will consolidate the information regarding diagnostic performance of fluciclovine PET/CT in a large number of prospectively followed patients at several centres in the UK and assess the effect of PSA level on the likelihood of detecting cancer lesions by fluciclovine (18F).

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT02578940

Sponsor: Blue Earth Diagnostics

Primary Outcome Measures:

  • Measure: Impact on patient treatment /management
  • Time Frame: 1 month
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Response rate to radical salvage therapy
  • Time Frame: 7 months
  • Safety Issue:
  • Measure: Diagnostic performance of the fluciclovine (18F) PET/CT scan
  • Time Frame: 1 month
  • Safety Issue:
  • Measure: Effect of PSA levels on detection of recurrent cancer by the fluciclovine (18F) PET/CT scan
  • Time Frame: 1 month
  • Safety Issue:
  • Measure: Assessment of safety and tolerability
  • Time Frame: 1 month
  • Safety Issue:
  • Measure: Comparison of detection rates for fluciclovine (18F) PET/CT and choline PET/CT (in the patient subset who receive choline as standard care)
  • Time Frame: 1 month
  • Safety Issue:

Estimated Enrollment: 180

Study Start Date: November 2015

Phase: Phase 3


  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • The subject has had an original diagnosis of PCa and underwent radical curative therapy at least 3 months before enrolment, and has been diagnosed with biochemical recurrence (BCR) on the basis of: 1. Post radical radiotherapy (RRT) / brachytherapy: Increase in PSA level ≥2.0 ng/mL above the nadir level after radiotherapy (RT) or brachytherapy (ASTRO-Phoenix criteria) [53], or 2. Post radical prostatectomy (RP): EITHER two consecutive rises in PSA and final PSA >0.1ng/ml OR three consecutive rises in PSA., This definition is also applicable to subjects with PSA persistence post RP (where the PSA fails to fall to undetectable levels). i. In addition, the subject post RP, should have a PSA doubling time of ≤15 months OR PSA level ≥1.0 ng/mL at time of recruitment. The PSA doubling time will be calculated using the Memorial Sloan Kettering Cancer Center nomogram (http://www.mskcc.org/nomograms/prostate/psa-doubling-time), based on a minimum of two PSA levels within 12 months of screening, taken after the last recorded nadir PSA available at time of screening.
  • The subject has not had previous recurrences of PCa, i.e. this is the first diagnosis of BCR.
  • The subject is being considered for radical salvage therapy.
  • The subject is able and willing to comply with study procedures, and signed, dated and timed informed consent is obtained before any study-related procedure is performed.
  • The subject's Eastern Cooperative Oncology Group [ECOG] performance status 0-2.
  • The subject should not have received androgen-deprivation therapy within 3 months of screening.
  • The subject has a normal or clinically acceptable medical history and vital signs findings at screening (up to 14 days before administration of study drug).

Exclusion Criteria:

  • The subject has been previously included in this study.
  • The subject has received, or is scheduled to receive, another investigational medicinal product (IMP) from 1 month before to 1 week after administration of fluciclovine (18F) injection.
  • The subject has known hypersensitivity to fluciclovine (18F) injection or any of its constituents.
  • The subject has had a choline PET/CT scan within 3 months of the screening visit.
  • The subject has bilateral hip prostheses.


  • Study Medical Director
  • +441865784186


  • Mount Vernon Cancer Centre, Mount Vernon Hospital
  • Northwood Middlesex HA6 2RN United Kingdom
  • Churchill Hospital
  • Oxford Oxfordshire OX3 7LE United Kingdom
  • Royal Marsden Hospital
  • Sutton Surrey SM2 5PT United Kingdom
  • St James Institute of Oncology
  • Leeds Yorkshire LS9 7TF United Kingdom
  • Greater Glasgow & Clyde NHS Trust
  • Glasgow United Kingdom
  • University College London Hospital
  • London NW1 2BU United Kingdom
  • St Thomas' Hospital
  • London SE1 7EH United Kingdom

View trial on ClinicalTrials.gov


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.